Pharmacological ReportsGenetic & Genomic MedicinePeer-reviewed journal article
preSCRIPT: Large-scale prescription search and annotation engine for pharmacogenomic studies
Maria Pieczarka, Paweł Pieńkowski, Paula Konowalska, Sylwia Grubarek, Jacek HajtoiD, Dżesika Hoinkis, Marcin PiechotaiD, Małgorzata BorczykiD, Michał KorostyńskiiD
Abstract
Pharmacogenetics (PGx) has traditionally focused on a small number of high-impact variants affecting drug response due to the fact that PGx studies are labor-intensive and therefore low-throughput. Population biobanks linked to electronic health records (EHRs), including the UK Biobank (UKB) with prescription data for [~]230,000 individuals offer opportunities to scale PGx research. This, however, comes with a challenge as EHRs do not provide direct treatment response outcomes. One way to overcome this is to draw indirect drug response phenotypes from prescription records. Here, we propose preSCRIPT, a framework to filter and annotate raw prescriptions from the UKB to derive phenotypes for analyses which includes an algorithm to distinguish short prescription gaps from true dose changes. As a proof of concept, we applied preSCRIPT to warfarin, paracetamol, codeine, amitriptyline, simvastatin, aspirin, and amlodipine and derived therapy length and median daily doses. We tested associations for those seven drugs and two phenotypes across SNPs, cytochrome P450 (CYP) genes, and HLA alleles. We replicated known associations such as CYP2D6 variants with amitriptyline therapy length and dose, CYP2C9/CYP4F2/CYP2C19 with warfarin dose, and CYP2D6 with codeine dose. For drugs without formal PGx guidelines, we identified an association between CYP2D6 activity and aspirin therapy length and several SNPs, including rs62471929 (CYP3A5), a variant for amlodipine dose, replicated in an independent hold-out set. Overall, our study shows that preSCRIPT can recover established PGx associations, prioritize exploratory novel candidate loci, and may serve as a tool for large-scale pharmacogenomics.
- organism: human
- assay: electronic health records
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 28th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population
Shefali S. Verma, Karl Keat, … Sony Tuteja·Journal of Translational MedicinePeer-reviewed·Nov 28, 2022
- Investigating the genetic factors of medication dosing using biobank-linked drug purchase data
Silva Kasela, Laura Birgit Luitva, … Maris Alver·medRxiv·Apr 1, 2025
- Pharmacogenetics at scale: An analysis of the UK Biobank
Gregory McInnes, Adam Lavertu, … Russ Biagio Altman·Clinical Pharmacology & TherapeuticsPeer-reviewed·Nov 25, 2020
- Genotype-predicted drug response phenotypes and their co-occurrence with dispensed medicines among 738,531 participants in the UK Our Future Health study
Christopher T. Rentsch, Krishnan Bhaskaran, … Munir Pirmohamed·medRxiv·Aug 12, 2026
- A LARGE-SCALE PHARMACOGENOMIC KNOWLEDGE GRAPH FOR DRUG-GENE-VARIANT-DISEASE DISCOVERY
Muhammad Omar Faruk·medRxiv·Sep 24, 2025
- Near, far, wherever you are: Phenotype-related variation in pharmacogenomic effect sizes across the psychiatric drug literature.
Siobhan K. Lock, Djenifer B. Kappel, … Antonio F. Pardiñas·Frontiers in PharmacologyPeer-reviewed·Jan 16, 2026